CN115969045A - Composition with weight health management function and preparation method and application thereof - Google Patents
Composition with weight health management function and preparation method and application thereof Download PDFInfo
- Publication number
- CN115969045A CN115969045A CN202111195980.1A CN202111195980A CN115969045A CN 115969045 A CN115969045 A CN 115969045A CN 202111195980 A CN202111195980 A CN 202111195980A CN 115969045 A CN115969045 A CN 115969045A
- Authority
- CN
- China
- Prior art keywords
- composition
- vitamin
- percent
- weight
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 230000036541 health Effects 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 123
- 230000004060 metabolic process Effects 0.000 claims abstract description 45
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims abstract description 43
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims abstract description 43
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims abstract description 43
- 230000001105 regulatory effect Effects 0.000 claims abstract description 43
- 244000269722 Thea sinensis Species 0.000 claims abstract description 33
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 33
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 32
- 229940054810 white kidney bean extract Drugs 0.000 claims abstract description 32
- 235000009569 green tea Nutrition 0.000 claims abstract description 30
- 235000020733 paullinia cupana extract Nutrition 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 16
- 230000001276 controlling effect Effects 0.000 claims abstract description 10
- 241000675108 Citrus tangerina Species 0.000 claims abstract 3
- 238000002156 mixing Methods 0.000 claims description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 32
- 239000007787 solid Substances 0.000 claims description 31
- 229920000294 Resistant starch Polymers 0.000 claims description 29
- 235000021254 resistant starch Nutrition 0.000 claims description 29
- 239000004375 Dextrin Substances 0.000 claims description 25
- 229920001353 Dextrin Polymers 0.000 claims description 25
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 25
- 235000019425 dextrin Nutrition 0.000 claims description 25
- 229920001202 Inulin Polymers 0.000 claims description 24
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 24
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 24
- 229940029339 inulin Drugs 0.000 claims description 24
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 24
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 15
- 229920002752 Konjac Polymers 0.000 claims description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 12
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 9
- 238000007908 dry granulation Methods 0.000 claims description 9
- 235000013312 flour Nutrition 0.000 claims description 9
- 229940013618 stevioside Drugs 0.000 claims description 9
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 9
- 235000019202 steviosides Nutrition 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 6
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 6
- 241000207199 Citrus Species 0.000 claims description 6
- 235000020971 citrus fruits Nutrition 0.000 claims description 6
- 239000000252 konjac Substances 0.000 claims description 6
- 235000010485 konjac Nutrition 0.000 claims description 6
- 238000005550 wet granulation Methods 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 54
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 6
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 36
- 241000220225 Malus Species 0.000 description 31
- 235000011430 Malus pumila Nutrition 0.000 description 30
- 235000015103 Malus silvestris Nutrition 0.000 description 30
- 239000003925 fat Substances 0.000 description 30
- 230000037396 body weight Effects 0.000 description 17
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 239000012265 solid product Substances 0.000 description 11
- 241001672694 Citrus reticulata Species 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229960001948 caffeine Drugs 0.000 description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 235000013824 polyphenols Nutrition 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 6
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 6
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 6
- 229940074393 chlorogenic acid Drugs 0.000 description 6
- 235000001368 chlorogenic acid Nutrition 0.000 description 6
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 6
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000037221 weight management Effects 0.000 description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 210000000579 abdominal fat Anatomy 0.000 description 5
- 229940030275 epigallocatechin gallate Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229930189775 mogroside Natural products 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000000593 adipose tissue white Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000533293 Sesbania emerus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- -1 cyclic oligosaccharide Chemical class 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 101000939438 Homo sapiens Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 125000003599 L-arabinosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)CO1)* 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 102100026639 MICOS complex subunit MIC60 Human genes 0.000 description 1
- 101710128942 MICOS complex subunit MIC60 Proteins 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 229940126902 Phlorizin Drugs 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020785 dietary preference Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 1
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 1
- 235000019139 phlorizin Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Images
Abstract
The invention discloses a composition with a weight health management function, which is characterized by comprising a composition for regulating sugar metabolism and a composition for regulating fat metabolism, wherein the mass ratio of the composition for regulating sugar metabolism to the composition for regulating fat metabolism is (0.1-5): 1; wherein the composition for regulating sugar metabolism comprises alpha-cyclodextrin, L-arabinose and white kidney bean extract; the composition for regulating fat metabolism comprises one or more of green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder and guarana extract. The invention also provides a preparation method and application of the composition. The product obtained by the composition can effectively manage the weight, abandons the traditional thought and method which only needs the weight but does not need to be healthy, and can stabilize the blood sugar while controlling the weight; protecting liver function; lowering blood lipids (triglycerides and low density lipoprotein cholesterol); resisting oxidation and removing free radicals; resisting virus, improving immunity, etc.
Description
Technical Field
The invention belongs to the technical field of weight management food and preparation thereof, and particularly relates to a composition with a weight health management function, and a preparation method and application thereof.
Background
The current society is an "overweight" society, which is an undoubted fact. Overweight can cause a range of problems such as hypertension, diabetes, fatty liver, heart disease, and the like. For the current generation of young people, weight loss is a mixed anxiety topic, and excessive diet, excessive exercise and drug abuse also become factors which cannot be circumvented in weight management. But it is noted that health is always an ultimate goal of weight management, and not just to maintain a so-called "S" shape, which is also most easily overlooked by people. People can reduce the total caloric intake by making personalized recipes and reducing food portions, and can also control weight through planned exercise. There are still "more comfortable" solutions that consumers are seeking without "holding the mouth" and "stepping the legs" away.
At present, weight management products on the market comprise common foods and beverages, dietary supplements, meal substitutes, weight-reducing tea, over-the-counter medicines and the like. The foods and beverages related to weight management are added with functional components or adjusted in nutritional composition, so that the guilt feeling of consumers during eating is reduced, or the declaration requirement of related health functions is met. Generally, the products sacrifice the mouthfeel in order to increase satiety, or require consumers to avoid dietetic or regular use for achieving efficacy, or add western medicine components illegally, and the use is repeated after the use is stopped, or only pay attention to the weight reduction level, and other factors influencing the weight are not regulated. The basic requirements of consumers on food attributes and functions are not considered, and health management control and regulation of body weight and the negative effects caused by weight gain are not involved from the physical overall mechanism level.
Therefore, it is now necessary to provide a composition, food, beverage, or the like which is healthy and can manage body weight well.
Disclosure of Invention
The invention aims to solve the problem that the existing weight management products cannot achieve the health and effect, and provides a composition with a weight health management function and a preparation method and application thereof. The composition of the invention abandons the traditional thought and method that the body weight is not healthy, aims to scientifically reduce the weight, regulate the whole metabolic level of the body, prevent the side effect caused by the weight increase and achieve the effect of healthy weight control.
The purpose of the invention and the technical problem to be solved are realized by adopting the following technical scheme.
One aspect of the present invention provides a composition having a weight health management function, the composition comprising a composition for regulating sugar metabolism and a composition for regulating fat metabolism, wherein the mass ratio of the composition for regulating sugar metabolism to the composition for regulating fat metabolism is (0.1-5): 1; wherein the composition for regulating sugar metabolism comprises alpha-cyclodextrin, L-arabinose and white kidney bean extract; the composition for regulating fat metabolism comprises one or more of green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder and guarana extract.
Preferably, the mass ratio of the composition for regulating the carbohydrate metabolism to the composition for regulating the fat metabolism can be adjusted according to the physical state and the dietary preference of consumers, and the metabolism can be precisely regulated and controlled by adjusting the ratio of the composition for regulating the carbohydrate metabolism to the composition for regulating the fat metabolism, so that the aim of weight health management is fulfilled.
According to the composition with the weight health management function, more attention is paid to improving body functions from the aspects of sugar metabolism, fat metabolism and the like, so that the aim of weight health control is fulfilled, and various negative effects caused by weight gain can be reduced. The composition with the weight health management function can be any one of tablets, solid beverages, liquid beverages and jellies.
The composition having weight health management function according to the present invention can achieve the desired effects without intentionally controlling the intake of carbohydrates and fats during the intake of the composition.
The composition with the weight health management function comprises one or more of alpha-cyclodextrin, L-arabinose, white kidney bean extract, green coffee concentrated powder, apple concentrated powder, green tea extract, tangerine powder and guarana extract.
Alpha-cyclodextrin is one of dietary fibers, a six-membered cyclic oligosaccharide produced by amylose under the action of cyclodextrin glucosyltransferase produced by bacillus. The alpha-cyclodextrin is used in the field of functional foods and pharmaceutical excipients as soluble dietary fiber or a material for improving metabolic syndrome, and the efficacy of reducing blood sugar concentration and the efficacy of losing weight are also authorized and market-approved.
The alpha-cyclodextrin can prevent the absorption of saccharides in the intestine, promote the excretion of the encapsulated saccharides, reduce the peak value of blood sugar after high-starch diet, and achieve the effect of inhibiting the increase of blood sugar after meal. The alpha-cyclodextrin has good effect on preventing and improving diabetes, and can be used as an effective hypoglycemic health food raw material for preventing postprandial hyperglycemia of hyperglycemia patients and type II diabetes patients. In the statement on the nutrition and health of food by the regulation No. 536 of european union 2013, it was confirmed that alpha-cyclodextrin was scientifically proven to have the effect of regulating blood sugar "eating a starch-containing meal containing alpha-cyclodextrin can reduce the rise of blood sugar after meal", if it is noted that a meal size of food contains at least 5 grams of alpha-cyclodextrin per 50 grams of starch, the producer allows to mark the product on the packaging as having the effect of reducing blood sugar.
The L-arabinose is a low-calorie sweetening agent, is widely present in the peel and the shell of fruits and coarse grains, can inhibit the activity of sucrase in intestinal tracts of human bodies, and has the effect of inhibiting the absorption of sucrose; in addition, L-arabinose can also inhibit body fat accumulation, so that it can be used for preventing and treating obesity, hypertension, hyperlipidemia and other diseases. L-arabinose is listed as a special health food additive for regulating blood sugar in Japan Kyoho; the American medical Association places L-arabinose as an "anti-obesity nutritional supplement or over-the-counter drug"; the Ministry of health of China officially approved L-arabinose as a new resource food in 2008, and confirmed the important position of the L-arabinose in the field of functional sugar.
The white kidney bean extract contains an alpha-amylase inhibitor, commonly called as a starch blocker, and can thoroughly block a channel of interaction between a substrate and an active site of the alpha-amylase, so that the activity of the alpha-amylase in a human oral cavity and pancreas is reduced, and starch cannot be completely decomposed into micromolecular monosaccharide to be absorbed by a human body, thereby achieving the purpose of controlling the starch to be converted into heat to be absorbed.
Therefore, according to the characteristics of in vivo sugar metabolism, the composition for regulating sugar metabolism preferably selects L-arabinose as a sucrose inhibitor source, and the white kidney bean extract as a starch inhibition source, firstly blocks sugar absorption, and then inhibits residual sugar inclusion in vivo through alpha-cyclodextrin, so that the aim of regulating sugar metabolism is fulfilled.
Preferably, the mass ratio of the alpha-cyclodextrin to the L-arabinose to the white kidney bean extract is (0.1-0.6) to (0.1-0.3): (0.1 to 0.5); by optimizing the mass ratio of the sucrose to the starch, the absorption and the transformation of the ingested sucrose and the ingested starch in the body can be obviously inhibited, and the energy generation and the accumulation are reduced, so that the weight gain is controlled.
Chlorogenic acid is depside generated from caffeic acid and quinic acid, and is a phenylpropanoid compound produced by plants in the aerobic respiration process through the shikimic acid pathway. In one study in the united states, subjects consumed a green cup of coffee daily before breakfast. After two weeks, the average body weight of these persons decreased by about 1.59 kg; after one month, the average body weight was more reduced by about 2.01 kg. The substance with weight reducing effect in the green coffee is chlorogenic acid. Chlorogenic acid mainly intervenes in the liver and intestine circulation of bile acid to achieve the effects of inhibiting and reducing fat absorption and increasing the absorption and metabolism of cholesterol, thereby achieving the effects of regulating blood fat and losing weight.
Epigallocatechin gallate (EGCG) is an important functional component in tea, and in recent years, researches of a large number of scientists at home and abroad prove that EGCG has a certain weight-losing effect. The main mechanism comprises: 1) Promoting thermogenesis, increasing energy metabolism, increasing fat decomposition, and promoting fatty acid oxidation; 2) Inhibiting energy intake, inhibiting adipocyte differentiation and adipogenesis; 3) Regulating leptin and resistin, inhibiting gluconeogenesis, and improving insulin sensitivity; 4) Reduce lipid absorption and increase lipid excretion.
Apple polyphenol is a generic term for polyphenols contained in apples. The apple polyphenol contains chlorogenic acid, catechin, epicatechin, apple condensed tannin, phlorizin, phloretin, anthocyanin, etc., wherein the apple condensed tannin accounts for about half of the total content of the polyphenol. The apple polyphenol lipid-reducing effect is mainly to inhibit the absorption of body to neutral fat and discharge the fat out of body by inhibiting lipase activity and reducing the absorption of visceral fat. Meanwhile, the apple polyphenol can reduce the deposition of lipid in arterial blood vessels, and ensure the elasticity and health of the blood vessels.
In the body, excess energy is stored in the form of triglycerides in white adipose tissue, resulting in overweight. Citrus fiber, in turn, enhances the breakdown of free fatty acids while eliminating the release of excess fat from white adipose tissue by increasing resting energy expenditure, i.e., higher caloric burn rate. Uncoupling protein is a mitochondrial inner membrane protein, generates heat and is highly expressed in brown fat cells, and citrus fiber can obviously enhance higher mitochondrial density and higher UCPs expression, thereby enhancing the heat conversion of white fat, enhancing the fat dissolution rate and accelerating the consumption of fat.
Caffeine, the most widely used psychoactive agent (a substance that affects brain function) at present, stimulates the central nervous system, and increases cognitive consciousness and physical alertness. Research shows that the caffeine has the efficacy of burning fat at the same time. When 200mg of caffeine is ingested, your metabolic rate will be increased by 7% in the next 3 hours, which means that the rate of fat burning will be greatly increased.
The caffeine sources are divided into natural sources and artificial synthesis, although the content of the artificial synthetic caffeine is high, the improper control of the excitement can cause certain damage to the body, and meanwhile, the excessive excitement can influence the mental concentration and the like. The natural source is safer and has no side effect compared with the synthetic caffeine.
According to the invention, the green coffee bean concentrated powder is preferably used as a chlorogenic acid source, the apple concentrated powder is used as an apple polyphenol source, the green tea concentrated powder is used as an EGCG source, the orange powder is used as a citrus fiber source, and the guarana extract is used as a natural caffeine source.
Preferably, the mass ratio of the green coffee concentrated powder, the apple concentrated powder, the green tea concentrated powder, the citrus powder and the guarana extract is (0.2-0.6): (0.1-0.3): (0-0.1): (0.1-0.3): (0 to 0.1); by optimizing the proportion, the fat absorption can be efficiently prevented, the burning and metabolism of the fat are accelerated, and the accumulation of the fat in the body is reduced.
The content of chlorogenic acid in the green coffee bean concentrated powder is more than or equal to 25 percent; the content of epigallocatechin gallate in the green tea concentrated powder is more than or equal to 94 percent; the polyphenol content in the apple concentrated powder is more than or equal to 50 percent; the guarana extract is water extract powder of guarana seed, and caffeine content is not less than 18%.
Preferably, the sum of the mass of the composition for regulating sugar metabolism and the mass of the composition for regulating fat metabolism accounts for 30-70% of the total mass of the composition with the weight health management function.
Preferably, the composition with the weight health management function further comprises auxiliary functional ingredients, wherein the auxiliary functional ingredients comprise inulin, konjac flour, resistant dextrin, resistant starch and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 One or more of.
The dietary fiber can be fermented and decomposed by intestinal microorganisms to change intestinal flora, and can chelate bile acid, cholesterol and some toxins to promote toxin discharge. In addition, it can increase intestinal peristalsis and promote defecation. By adding the auxiliary functional components, the sugar metabolism regulating composition and the fat metabolism regulating composition can have a synergistic effect, increase in vivo circulation, and perform comprehensive regulation and more comprehensive metabolic regulation. The resistant starch is natural resistant starch RS 2 Powder product with content of above 50%, preferably RS with content of above 70% 2 . The addition of the auxiliary functional components can assist the action of the sugar metabolism and fat metabolism modules, accelerate metabolism and ensure the efficient operation of the whole process.
Vitamin B1 and vitamin B2 are indispensable components in energy metabolism, and can help digestion of carbohydrate so as to provide enough energy for people; vitamin B6 contributes to the metabolism and utilization of proteins, it contributes to energy production, and it is energetic; vitamin B12 aids in erythropoiesis, and at the same time may eliminate irritation, help focus attention, and enhance memory. The supplement of the B vitamins can participate in the metabolism of sugar, protein and fat in vivo, is helpful for promoting metabolism, and has the function of the composition with the body weight health management function.
In the invention, the composition with the weight health management function also has the auxiliary functions of: stabilizing blood sugar; protecting liver function; lowering blood lipids (triglycerides and low density lipoprotein cholesterol); resisting oxidation and scavenging free radicals; resisting virus, improving immunity, etc.
As one specific embodiment of the invention, the composition with the weight health management function comprises the following components in parts by weight: 1 to 9 portions of alpha-cyclodextrin, 1 to 6 portions of resistant dextrin, 0 to 6 portions of inulin, 1 to 6 portions of L-arabinose, 0 to 6 portions of resistant starch, 0 to 6 portions of konjaku flour, 1 to 5 portions of green coffee concentrate, 0.1 to 2 portions of orange powder, 0.1 to 4 portions of apple concentrate, 0.05 to 1 portion of green tea concentrate, 0.04 to 1 portion of guarana extract, 0.1 to 3 portions of white kidney bean extract, vitamin B 1 0.00018 to 0.00044 portion of vitamin B 2 0.00018 to 0.00044 portion of vitamin B 6 0.00014 to 0.0005 portion and vitamin B 12 0.2～1.32×10 -6 And (4) portions are obtained.
As one of the preferred embodiments of the present invention, the composition with the weight health management function comprises the following components in parts by weight: 1 to 6 portions of alpha-cyclodextrin, 1 to 4 portions of resistant dextrin, 0 to 3 portions of inulin, 1 to 3 portions of L-arabinose, 0 to 4 portions of resistant starch, 0 to 2 portions of konjaku flour, 1 to 3 portions of green coffee concentrate, 0.1 to 2 portions of white kidney bean extract, 0.5 to 2 portions of orange powder, 0.5 to 4 portions of apple concentrate, 0.05 to 0.5 portion of green tea concentrate, 0.04 to 0.2 portion of guarana extract, vitamin B 1 0.0002 to 0.0004 portion of vitamin B 2 0.0002 to 0.0004 portion of vitamin B 6 0.0002 to 0.0004 portion of vitamin B 12 0.5～1×10 -6 And (4) portions.
Preferably, the composition with the weight health management function further comprises an auxiliary material, wherein the auxiliary material is one or more of a sweetening agent, an acidity agent, a stabilizer, a thickening agent and a food essence.
In another aspect of the present invention, there is provided a method for preparing a composition having weight health management function, the method comprising the steps of:
and (3) granulating: mixing part of alpha-cyclodextrin in the composition for regulating and controlling sugar metabolism with L-arabinose and white kidney bean extract according to the ratio of alpha-cyclodextrin: the L-arabinose + white kidney bean extract is 1:1, and performing dry granulation to obtain solid particles A; uniformly mixing the green coffee concentrated powder, the apple concentrated powder, the green tea concentrated powder, the tangerine powder and the guarana extract in the fat metabolism regulating and controlling composition with the rest alpha-cyclodextrin, and performing dry granulation to obtain solid particles B;
mixing: mixing the obtained solid granule A and solid granule B with inulin, resistant dextrin, resistant starch, rhizoma Amorphophalli powder, and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Mixing according to the proportion, and performing wet granulation to obtain solid granules of the final composition.
The invention combines the characteristics of the raw materials, and adopts different granulating methods and mixing methods, thereby being more beneficial to the uniform mixing of the materials and the release of the efficacy, and simultaneously, the composition has good instant solubility and fluidity and is beneficial to the application of rear-end products.
Wherein, in the dry granulation process, the mesh number of solid particles is controlled to be 20-80 meshes, and in the wet granulation process, the mesh number of particles is controlled to be 30-60 meshes. Under the condition, the composition is favorably and fully mixed uniformly, the fluidity and the instant solubility are ensured, and a foundation is provided for the subsequent application.
Another aspect of the present invention also provides a use of the composition with weight health management function according to the above or the method for preparing the composition with weight health management function in preparing food, health products and dietary supplements.
As one of the specific embodiments of the invention, the application also comprises the toolThe application of the composition with the weight health management function in preparing the beverage comprises the following components in percentage by weight: 0.5 to 4 percent of alpha-cyclodextrin, 0.1 to 1 percent of L-arabinose, 0.2 to 0.6 percent of white kidney bean extract, 0.3 to 1 percent of green coffee concentrated powder, 0.05 to 0.3 percent of apple concentrated powder, 0.02 to 0.1 percent of green tea concentrated powder, 0.15 to 0.6 percent of orange powder, 0.01 to 0.08 percent of guarana extract, 0.5 to 2 percent of inulin, 0.2 to 1 percent of resistant dextrin, 0.2 to 1 percent of konjaku flour, vitamin B 1 0.00007-0.00018 percent of vitamin B 2 0.00007-0.0002% of vitamin B 6 0.00007-0.0002% of vitamin B 12 0.08×10 -6 ～0.5×10 -6 0.2 to 1 percent of resistant starch, 0.01 to 0.07 percent of sodium carboxymethylcellulose, 0.04 to 0.3 percent of citric acid, 0.01 to 0.05 percent of sodium citrate, 0.01 to 0.06 percent of stevioside and 0.1 to 0.4 percent of essence for food.
As one of the preferred embodiments of the invention, the beverage comprises the following components in percentage by weight: 1 to 4 percent of alpha-cyclodextrin, 0.4 to 1 percent of L-arabinose, 0.2 to 0.5 percent of white kidney bean extract, 0.5 to 1 percent of green coffee concentrated powder, 0.1 to 0.3 percent of apple concentrated powder, 0.05 to 0.1 percent of green tea concentrated powder, 0.2 to 0.4 percent of orange powder, 0.01 to 0.06 percent of guarana extract, 0.5 to 1.5 percent of inulin, 0.5 to 1 percent of resistant dextrin, 0.5 to 1 percent of konjac powder, and vitamin B 1 0.00009-0.00018% of vitamin B 2 0.00009-0.0002% of vitamin B 6 0.00007-0.00015% of vitamin B 12 0.1×10 -6 ～0.45×10 -6 0.5 to 1 percent of resistant starch, 0.06 to 0.2 percent of citric acid, 0.02 to 0.05 percent of sodium citrate, 0.03 to 0.07 percent of sodium carboxymethyl cellulose, 0.01 to 0.05 percent of stevioside and 0.1 to 0.3 percent of essence for food.
As one of the preferred embodiments of the invention, the beverage comprises the following components in percentage by weight: 1 to 3 percent of alpha-cyclodextrin, 0.5 to 1 percent of L-arabinose, 0.25 to 0.5 percent of white kidney bean extract, 0.5 to 0.8 percent of green coffee concentrated powder, 0.15 to 0.3 percent of apple concentrated powder, 0.05 to 0.8 percent of green tea concentrated powder and 0.25 to 0.4 percent of orange powder0.02-0.06% of guarana extract, 0.6-1.5% of inulin, 0.6-1% of resistant dextrin, 0.6-1% of konjac flour, 0.6-1% of resistant starch, and vitamin B 1 0.0001-0.00018% of vitamin B 2 0.0001-0.00018 percent of vitamin B 6 0.00008-0.00012 percent of vitamin B 12 0.1×10 -6 ～0.4×10 -6 Percent, 0.5 to 0.85 percent of resistant starch, 0.08 to 0.2 percent of citric acid, 0.02 to 0.043 percent of sodium citrate, 0.03 to 0.06 percent of sodium carboxymethylcellulose, 0.01 to 0.04 percent of stevioside and 0.1 to 0.26 percent of essence for food.
Preferably, the essence can be liquid essence or powder essence, and is selected from one or more of fructus Lycii essence, ginseng radix Rubri essence, fructus Musae essence, red ox essence, fructus Citri Limoniae essence, green tea essence, black tea essence, fructus Persicae essence, fructus Jujubae essence, citrus reticulata essence, and mogitou essence. The sweetener may be one or more of stevioside, mogroside, psicose, erythritol, neohesperidin, and thaumatin.
By means of the technical scheme, the invention at least has the following advantages: the composition comprises a composition for regulating carbohydrate metabolism and a composition for regulating fat metabolism, the two compositions can be used as effective components to effectively manage the body weight, the traditional thought and method that the body weight is not healthy are abandoned, and the blood sugar can be stabilized while the body weight is controlled; protecting liver function; lowering blood lipids (triglycerides and low density lipoprotein cholesterol); resisting oxidation and scavenging free radicals; resisting virus, improving immunity, etc. The composition can be applied to the fields of food, health products, dietary supplements and the like. Meanwhile, the invention also provides a novel preparation method, under the preparation method, all components of the mixture can be fully and uniformly mixed, the flavor of the product can be retained to the maximum extent, and the loss of the product in the conventional preparation process can be avoided; meanwhile, the mixture has uniform granularity and good fluidity, and is convenient to be applied to other products.
The foregoing description is only an overview of the technical solutions of the present invention, and in order to make the technical solutions of the present invention more clearly understood and to be implemented in accordance with the contents of the description, the following detailed description is given with reference to the preferred embodiments of the present invention and the accompanying drawings.
Drawings
FIG. 1 is a graph showing the effect of various dosages of the composition having weight health management function according to the preparation method of example 1 of the present invention on the body weight of rats;
FIG. 2 is a graph showing the effect of the composition having a weight health management function on the abdominal fat weight of a mouse according to the preparation method of example 1 of the present invention;
FIG. 3 is a graph showing the effect of the composition having a weight health management function on the weight of the liver of a mouse according to the preparation method of example 1 of the present invention;
FIG. 4 is a graph showing the effect of a composition having a weight health management function on total serum cholesterol in the liver of a mouse, obtained according to the preparation method of example 1 of the present invention;
FIG. 5 is a graph showing the effect of a composition for health management of body weight on serum low density lipoprotein, obtained according to the preparation method of example 1 of the present invention;
fig. 6 is a graph showing the effect of the composition having a weight health management function on serum triglycerides according to the preparation method of example 1 of the present invention.
Detailed Description
In order to make the technical means, the creation features, the achievement purposes and the effects of the invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention and the accompanying drawings. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The embodiment provides a solid product with weight health management function, which comprises the following components in percentage by weight:
the main components are as follows: 2.5% of alpha-cyclodextrin, 0.8% of L-arabinose, 0.5% of white kidney bean extract, 0.6% of green coffee concentrated powder, 0.3% of apple concentrated powder, 0.05% of green tea concentrated powder, 0.4% of orange powder and 0.04% of guarana extract;
auxiliary components: inulin 1%, resistant dextrin 0.6%, rhizoma Amorphophalli powder 0.6%, and vitamin B 1 0.00017%, resistant starch 0.9%, vitamin B 2 0.00017% vitamin B 6 0.0001%, vitamin B 12 0.14×10 -6 ％；
Auxiliary materials: 0.18% of citric acid, 0.04% of sodium citrate, 0.045% of sodium carboxymethyl cellulose, 0.02% of stevioside and 0.15% of essence for food.
The preparation method comprises the following steps:
and (3) granulating: respectively mixing the raw materials in the mixture component according to the weight percentage, mixing the alpha-cyclodextrin: l-arabinose: the white kidney bean extract is uniformly mixed according to the proportion of 1.3; uniformly mixing the weighed green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder and guarana extract with the rest part of alpha-cyclodextrin, and performing dry granulation to control the particle size to be 60 meshes to obtain solid particles B;
mixing: mixing inulin, resistant dextrin, resistant starch, rhizoma Amorphophalli powder, and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Mixing the mixture with the solid particles A, the solid particles B and all auxiliary materials uniformly, and performing wet granulation to control the particle size to be 30 meshes to obtain the solid particles of the composition, namely the solid product with the weight health management function.
Example 2
The embodiment provides a solid product with weight health management function, which comprises the following components in percentage by weight:
the main components are as follows: 2% of alpha-cyclodextrin, 0.6% of L-arabinose, 0.3% of white kidney bean extract, 0.6% of green coffee concentrated powder, 0.28% of apple concentrated powder, 0.07% of green tea concentrated powder, 0.3% of orange powder and 0.035% of guarana extract;
auxiliary components: inulin 0.8%, resistant dextrin 0.5%, rhizoma Amorphophalli powder 0.6%, and vitamin B 1 0.00018 percent of resistant starch, 0.8 percent of vitamin B 2 0.00018 percent of vitamin B 6 0.00012 percent of vitamin B 12 0.15×10 -6 ％；
Auxiliary materials: 0.2% of citric acid, 0.05% of sodium citrate, 0.04% of sodium carboxymethylcellulose, 0.028% of psicose and 0.2% of food essence.
The preparation method comprises the following steps:
and (3) granulating: respectively mixing the raw materials in the mixture component according to the weight fraction, mixing the alpha-cyclodextrin: l-arabinose: the white kidney bean extract is uniformly mixed according to the proportion of 1.3; uniformly mixing the weighed green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder and guarana extract with the rest part of alpha-cyclodextrin, and performing dry granulation to control the particle size to be 70 meshes to obtain solid particles B;
mixing: mixing inulin, resistant dextrin, resistant starch, rhizoma Amorphophalli powder, and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Mixing the mixture with the solid particles A, the solid particles B and all auxiliary materials uniformly, granulating by a wet method, and controlling the particle size to be 25 meshes to obtain the solid particles of the composition, namely the solid product with the weight health management function.
Example 3
The embodiment provides a solid product with weight health management function, which comprises the following components in percentage by weight:
the main components are as follows: 1.8% of alpha-cyclodextrin, 0.55% of L-arabinose, 0.35% of white kidney bean extract, 0.65% of green coffee concentrated powder, 0.2% of apple concentrated powder, 0.04% of green tea concentrated powder, 0.25% of orange powder and 0.03% of guarana extract;
auxiliary components: inulin 0.9%, resistant dextrin 0.55%, rhizoma Amorphophalli powder 0.5%, and vitamin B 1 0.00015 percent of resistant starch, 0.8 percent of vitamin B 2 0.00015% of vitaminElement B 6 0.0001%, vitamin B 12 0.2×10 -6 ％；
Auxiliary materials: 0.25% of citric acid, 0.06% of sodium citrate, 0.045% of sodium carboxymethylcellulose, 0.03% of mogroside and 0.25% of food essence.
The preparation method comprises the following steps:
and (3) granulating: mixing the raw materials in the mixture according to the weight percentage, mixing the alpha-cyclodextrin: l-arabinose: the white kidney bean extract is uniformly mixed according to the proportion of 1.3; uniformly mixing the weighed green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder and guarana extract with the rest part of alpha-cyclodextrin, and performing dry granulation to obtain solid granules B with the particle size of 80 meshes.
Mixing: mixing inulin, resistant dextrin, resistant starch, rhizoma Amorphophalli powder, and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Mixing the mixture with the solid particles A, the solid particles B and all auxiliary materials uniformly, and performing wet granulation to control the particle size to be 30 meshes to obtain the solid particles of the composition, namely the solid product with the weight health management function.
Example 4
The embodiment provides a solid product with weight health management function, which comprises the following components in percentage by weight:
the main components are as follows: 2% of alpha-cyclodextrin, 0.8% of L-arabinose, 0.35% of white kidney bean extract, 0.6% of green coffee concentrated powder, 0.24% of apple concentrated powder, 0.06% of green tea concentrated powder, 0.36% of orange powder and 0.04% of guarana extract;
auxiliary components: inulin 1.1%, resistant dextrin 0.75%, rhizoma Amorphophalli powder 0.5%, and vitamin B 1 0.00014 percent of resistant starch, 0.8 percent of vitamin B 2 0.00014 percent of vitamin B 6 0.00008% of vitamin B 12 0.3×10 -6 ％；
Auxiliary materials: 0.18 percent of citric acid, 0.03 percent of sodium citrate, 0.04 percent of sodium carboxymethylcellulose, 0.02 percent of mogroside and 0.3 percent of essence for food.
The preparation method comprises the following steps:
granulating: mixing the raw materials in the mixture according to the weight percentage, mixing the alpha-cyclodextrin: l-arabinose: the white kidney bean extract is uniformly mixed according to the proportion of 1.3; uniformly mixing the weighed green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder and guarana extract with the rest part of alpha-cyclodextrin, and performing dry granulation to obtain solid granules B with the particle size of 80 meshes.
Mixing: mixing inulin, resistant dextrin, resistant starch, rhizoma Amorphophalli powder, and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Mixing the mixture with the solid particles A, the solid particles B and all auxiliary materials uniformly, and performing wet granulation to control the particle size to be 30 meshes to obtain the solid particles of the composition, namely the solid product with the weight health management function.
Example 5
The embodiment provides a liquid product with weight health management function, which comprises the following components in parts by weight:
the main components are as follows: 2% of alpha-cyclodextrin, 0.75% of L-arabinose, 0.4% of white kidney bean extract, 0.64% of green coffee concentrated powder, 0.24% of apple concentrated powder, 0.04% of green tea concentrated powder, 0.36% of citrus powder and 0.035% of guarana extract;
auxiliary components: inulin 1.2%, resistant dextrin 0.8%, rhizoma Amorphophalli powder 0.7%, and vitamin B 1 0.00012 percent of resistant starch, 0.8 percent of vitamin B 2 0.00012 percent of vitamin B 6 0.00009% of vitamin B 12 0.35×10 -6 ％；
Auxiliary materials: 0.2% of citric acid, 0.03% of sodium citrate, 0.04% of sodium carboxymethylcellulose, 0.015% of stevioside and 0.2% of food essence.
The preparation method comprises the following steps:
blending: in the blending tank, the alpha-ring is mixedMixing dextrin, L-arabinose, white kidney bean extract, green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder, inulin, resistant dextrin, konjaku flour and resistant starch, and dissolving with water at 60 ℃, wherein the ratio of the material to the liquid is 1:80; mixing small materials including sodium carboxymethylcellulose, stevioside, guarana extract, and vitamin B 1 Resistant starch, vitamin B 2 Vitamin B 6 Vitamin B 12 Dissolving in advance, sequentially adding into a blending tank, and stirring uniformly; preparing 10% acid solution from citric acid and sodium citrate, and adjusting acid; and finally, adding essence for flavoring to obtain the feed liquid.
Sterilization and cooling: homogenizing the above liquid at 70 deg.C under 20MPa, sterilizing at 125 deg.C under 10sUHT, and cold packaging to obtain the final product with weight health management function.
Example 6
The embodiment provides a liquid product with weight health management function, which comprises the following components in parts by weight:
the main components are as follows: 2.5% of alpha-cyclodextrin, 0.8% of L-arabinose, 0.45% of white kidney bean extract, 0.7% of green coffee concentrated powder, 0.3% of apple concentrated powder, 0.04% of green tea concentrated powder, 0.4% of orange powder and 0.04% of guarana extract;
auxiliary components: inulin 1.2%, resistant dextrin 0.6%, rhizoma Amorphophalli powder 0.6%, and vitamin B 1 0.00018 percent of resistant starch, 0.9 percent of vitamin B 2 0.00018 percent of vitamin B 6 0.00012 percent of vitamin B 12 0.25×10 -6 ％；
Auxiliary materials: 0.18% of citric acid, 0.04% of sodium citrate, 0.045% of sodium carboxymethylcellulose, 0.02% of mogroside and 0.25% of food essence.
The preparation method comprises the following steps:
blending: in a blending tank, mixing alpha-cyclodextrin, L-arabinose, white kidney bean extract, green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, tangerine powder, inulin, resistant dextrin, konjac powder and resistant starch, and dissolving with water at 60 ℃, wherein the ratio of material to liquid is 1:100; mixing small materials including sodium carboxymethylcellulose, stevioside, guarana extract, and vitamin B 1 Resistant starch, vitamin B 2 Vitamin B 6 Vitamin B 12 Dissolving in advance, sequentially adding into a blending tank, and stirring uniformly; preparing 10% acid solution from citric acid and sodium citrate, and adjusting acid; and finally, adding essence for flavoring to obtain the feed liquid.
Sterilization and cooling: homogenizing the above liquid at 70 deg.C under 20MPa, sterilizing at 125 deg.C under 10sUHT, and cold packaging to obtain the final product with weight health management function.
Test example 1 Effect of products having health-promoting function on rat body weight
Subject: the solid product with health management function prepared in example 1.
The experimental method comprises the following steps: 60 male rats of 8 weeks of age were selected and randomly divided into 4 groups of 15 rats each. The average rat weight of the normal control group is 264 plus or minus 0.22g, the average rat weight of the low-dose experimental group is 269 plus or minus 0.34g, the average rat weight of the medium-dose experimental group is 270 plus or minus 0.29g, and the average rat weight of the high-dose experimental group is 274 plus or minus 0.43g. Each group of experimental rats was fed with feed.
Normal control group: feeding the feed normally; low dose experimental group: 2.5g of the solid particles of example 1 are taken twice a day per dose; middle dose experimental group: each dose was 5g of the solid particles of example 1 twice daily; high dose experimental group: each dose was 7.5g of the solid particles of example 1 taken twice daily. The recording was observed for 7 days as a cycle, and was continuously observed for 12 weeks.
The experimental results are as follows: the change in body weight of rats is shown in fig. 1 (P <0.05, n = 15).
Fig. 1 is a graph showing the influence of different dosages of the composition having the weight health management function according to the preparation method of example 1 of the present invention on the body weight of rats. As can be seen from FIG. 1, the composition of example 1 of the present invention has a significant weight loss effect; compared with the taking dosage, the solid particles with low taking dosage have more obvious weight-losing effect compared with the medium and high taking dosages; the weight reduction rate of the medium-dose experimental group and the high-dose experimental group is not obvious, and the administration dosage has an upper limit on the weight control effect. Meanwhile, through experimental observation, the rats in the experimental group do not have the undesirable symptoms of inappetence, listlessness, diarrhea and the like in the process of taking the solid product of the composition.
Test example 2 Effect of products having health-promoting function on Metabolic syndrome
Subject: the composition having health management function prepared in example 1.
The experimental method comprises the following steps: the C57BL/6 mouse is a common model for studying obesity and metabolic syndrome, and the mouse develops significant overweight and obesity phenomena after being fed with high-fat diet for 6 weeks. Based on this model, studies have shown that long-term intake (8-22 weeks) of high-dose proprietary compositions in C57BL/6 mice fed high-fat diet can significantly reduce abdominal fat weight as well as serum total cholesterol and low-density lipoproteins.
Male C57BL/6 mice (20.23 ± 0.11 g) at 6 weeks of age were randomly divided into three groups of 16 mice each, a low fat group (fed with low fat diet), a high fat group (fed with high fat diet), and a high fat + composition pellet group (fed with high fat diet supplemented with 10% of composition pellets), and all mice were fed with pure water and were fed freely. At 8 weeks of experiment, fasting for 12 hours, 8 mice per group were sacrificed under anesthesia, the remainder were fed for another 14 weeks, fasted for 12 hours, and all mice were sacrificed. The results of examining the mouse abdominal fat weight, liver weight, and the contents of total cholesterol, triglyceride, and low density lipoprotein in serum are shown in FIGS. 2 to 6.
FIG. 2 is a graph showing the effect of a composition having a weight health management function on the abdominal fat weight of a mouse, obtained according to the preparation method of example 1 of the present invention; FIG. 3 is a graph showing the effect of the composition having a weight health management function on the weight of the liver of a mouse according to the preparation method of example 1 of the present invention; FIG. 4 is a graph showing the effect of the composition having a weight health management function on total serum cholesterol in the liver of a mouse according to the preparation method of example 1 of the present invention; FIG. 5 is a graph showing the effect of the composition having a weight health management function on serum low density lipoprotein, obtained according to the preparation method of example 1 of the present invention; fig. 6 is a graph showing the effect of the composition having a weight health management function on serum triglycerides according to the preparation method of example 1 of the present invention. As shown in fig. 2 to 6, after the composition of example 1 of the present invention is used for the prognosis of high fat-induced C57BL/6 mice, the abdominal fat weight, liver weight, total cholesterol, triglyceride and low density lipoprotein content of the mice are all significantly reduced, which indicates that the composition of the present invention can not only control body weight, but also effectively inhibit the increase of body fat and blood fat, and has a certain improvement effect on fatty liver caused by obesity, thereby comprehensively regulating the body.
Test example 3 Effect of products having health management function on body weight variation
Subject: solid products having health management function prepared in examples 1 to 4
The experimental method comprises the following steps: selecting 150 obese persons as a subject, randomly dividing the subject into 4 experimental groups and 1 control group according to the weight and the body fat weight of the subject, wherein each group contains 30 persons, and the experimental groups take the test samples of examples 1, 2, 3 and 4 (respectively corresponding to the experimental groups 1 to 4) according to a human recommended method; the control group received an equal amount of placebo for 60 consecutive days during the test period with normal diet and work and rest.
And (4) measuring the body weight and the body fat content of the tested human body after the test is finished. The health state of the testee is not affected before and after the experiment, and the trace elements in the body meet the standard. Table 1 is a statistical table of test results. All experimental data are presented as mean ± standard deviation, data were statistically processed using the SPSS 16.0 statistical analysis software package, and comparisons between groups were performed using one-way anova. The check level was set to α =0.05, P > -0.05 difference was not significant, and P <0.05 difference was significant.
TABLE 1 weight and body fat Rate Change
| Body weight | Body fat | |
| Experimental group | ||
| 1 | Lightening by 10kg | The reduction is 12 percent |
| |
Lightening 7.5kg | The reduction is 5 percent |
| |
Lightening 6.2kg | The reduction is 3 percent |
| |
Lightening 9kg | The reduction is 7 percent |
| Control group | Lightening by 2kg | Without obvious change |
As can be seen from the results in table 1, the product of the present invention is effective in aiding weight health loss.
Although the present invention has been described with reference to a preferred embodiment, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (10)
1. The composition with the weight health management function is characterized by comprising a composition for regulating sugar metabolism and a composition for regulating fat metabolism, wherein the mass ratio of the composition for regulating sugar metabolism to the composition for regulating fat metabolism is (0.1-5): 1; wherein the composition for regulating and controlling sugar metabolism comprises alpha-cyclodextrin, L-arabinose and white kidney bean extract; the composition for regulating and controlling fat metabolism comprises one or more of green coffee concentrated powder, apple concentrated powder, green tea concentrated powder, citrus powder and guarana extract.
2. The composition with the weight health management function according to claim 1, wherein the mass ratio of the alpha-cyclodextrin, the L-arabinose and the white kidney bean extract is (0.1-0.6) to (0.1-0.3): (0.1 to 0.5); the mass ratio of the green coffee concentrated powder, the apple concentrated powder, the green tea concentrated powder, the tangerine powder and the guarana extract is (0.2-0.6): (0.1-0.3): (0-0.1): (0.1-0.3): (0-0.1).
3. The composition with weight health management function according to claim 1 or 2, wherein the sum of the mass of the composition for regulating sugar metabolism and the composition for regulating fat metabolism accounts for 30 to 70% of the total mass of the composition with weight health management function.
4. The composition with weight health management function according to claim 1 or 2, wherein the composition with weight health management function further comprises auxiliary functional ingredients, and the auxiliary functional ingredients comprise inulin, konjac flour, resistant dextrin, resistant starch, vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 One or more of.
5. The composition with the weight health management function according to claim 4, wherein the composition with the weight health management function comprises the following components in parts by weight: 1 to 9 portions of alpha-cyclodextrin, 1 to 6 portions of resistant dextrin, 0 to 6 portions of inulin, 1 to 6 portions of L-arabinose, 0 to 6 portions of resistant starch, 0 to 6 portions of konjaku flour, 1 to 5 portions of green coffee concentrate, 0.1 to 2 portions of orange powder, 0.1 to 4 portions of apple concentrate, 0.05 to 1 portion of green tea concentrate, 0.04 to 1 portion of guarana extract, 0.1 to 3 portions of white kidney bean extract, vitamin B 1 0.00018 to 0.00044 portion of vitamin B 2 0.00018 to 0.00044 portion of vitamin B 6 0.00014 to 0.0005 portion and vitamin B 12 0.2～1.32×10 -6 And (4) portions are obtained.
6. The composition with the weight health management function according to claim 4, wherein the composition with the weight health management function comprises the following components in parts by weight: 1 to 6 portions of alpha-cyclodextrin, 1 to 4 portions of resistant dextrin, 0 to 3 portions of inulin, 1 to 3 portions of L-arabinose, 0 to 4 portions of resistant starch, 0 to 2 portions of konjaku flour, 1 to 3 portions of green coffee concentrate, 0.1 to 2 portions of white kidney bean extract, 0.5 to 2 portions of orange powder, 0.5 to 4 portions of apple concentrate, 0.05 to 0.5 portion of green tea concentrate, 0.04 to 0.2 portion of guarana extract, vitamin B 1 0.0002 to 0.0004 portion of vitamin B 2 0.0002 to 0.0004 portion of vitamin B 6 0.0002 to 0.0004 portion of vitamin B 12 0.5～1×10 -6 And (4) portions are obtained.
7. The composition with the weight health management function according to claim 1 or 2, wherein the composition with the weight health management function further comprises an auxiliary material, and the auxiliary material is one or more of a sweetening agent, an acidity agent, a stabilizer, a thickening agent and a food essence.
8. A method for preparing the composition with weight health management function according to any one of claims 1 to 7, which comprises the following steps:
and (3) granulating: mixing part of alpha-cyclodextrin in the composition for regulating and controlling sugar metabolism with L-arabinose and white kidney bean extract according to the ratio of alpha-cyclodextrin: the L-arabinose + white kidney bean extract is 1:1, and performing dry granulation to obtain solid particles A; uniformly mixing the green coffee concentrated powder, the apple concentrated powder, the green tea concentrated powder, the tangerine powder and the guarana extract in the fat metabolism regulating and controlling composition with the rest alpha-cyclodextrin, and performing dry granulation to obtain solid particles B;
mixing: mixing the solid granules A and B with inulin, resistant dextrin, resistant starch, rhizoma Amorphophalli powder, and vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Mixing according to the proportion, and performing wet granulation to obtain solid granules of the final composition.
9. Use of the composition with weight health management function according to any one of claims 1 to 7 or the composition with weight health management function prepared by the method for preparing the composition with weight health management function according to claim 8 in the preparation of food, health products and dietary supplements.
10. The use according to claim 9, further comprising the use of a composition with weight health management function in the preparation of a beverage comprising, in weight percent: 0.5 to 4 percent of alpha-cyclodextrin, 0.1 to 1 percent of L-arabinose, 0.2 to 0.6 percent of white kidney bean extract, 0.3 to 1 percent of green coffee concentrated powder, 0.05 to 0.3 percent of apple concentrated powder, 0.02 to 0.1 percent of green tea concentrated powder, 0.15 to 0.6 percent of orange powder, 0.01 to 0.08 percent of guarana extract, 0.5 to 2 percent of inulin, 0.2 to 1 percent of resistant dextrin, 0.2 to 1 percent of konjac powder, and vitamin B 1 0.00007-0.00018% of vitamin B 2 0.00007-0.0002% vitaminBiotin B 6 0.00007-0.0002% of vitamin B 12 0.08×10 -6 ～0.5×10 -6 0.2 to 1 percent of resistant starch, 0.01 to 0.07 percent of sodium carboxymethylcellulose, 0.04 to 0.3 percent of citric acid, 0.01 to 0.05 percent of sodium citrate, 0.01 to 0.06 percent of stevioside and 0.1 to 0.4 percent of essence for food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111195980.1A CN115969045A (en) | 2021-10-14 | 2021-10-14 | Composition with weight health management function and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111195980.1A CN115969045A (en) | 2021-10-14 | 2021-10-14 | Composition with weight health management function and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115969045A true CN115969045A (en) | 2023-04-18 |
Family
ID=85966774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111195980.1A Pending CN115969045A (en) | 2021-10-14 | 2021-10-14 | Composition with weight health management function and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115969045A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048884A (en) * | 2010-12-16 | 2011-05-11 | 北京康比特体育科技股份有限公司 | Weight-losing composition containing guarana extract |
| KR20120022085A (en) * | 2010-08-25 | 2012-03-12 | 주식회사 인섹트 바이오텍 | Formulations for prevention or treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts of glycine max leaves as an active ingredient |
| CN103735687A (en) * | 2013-12-30 | 2014-04-23 | 北京康比特体育科技股份有限公司 | Slimming composition and preparation method thereof |
| CN103735739A (en) * | 2013-12-27 | 2014-04-23 | 北京康比特体育科技股份有限公司 | Slimming composition and preparation method thereof |
| CN107156586A (en) * | 2017-06-02 | 2017-09-15 | 江苏朸健生命科技发展有限公司 | Advantageously reduce solid beverage of blood glucose and regulation blood fat and preparation method thereof |
-
2021
- 2021-10-14 CN CN202111195980.1A patent/CN115969045A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120022085A (en) * | 2010-08-25 | 2012-03-12 | 주식회사 인섹트 바이오텍 | Formulations for prevention or treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts of glycine max leaves as an active ingredient |
| CN102048884A (en) * | 2010-12-16 | 2011-05-11 | 北京康比特体育科技股份有限公司 | Weight-losing composition containing guarana extract |
| CN103735739A (en) * | 2013-12-27 | 2014-04-23 | 北京康比特体育科技股份有限公司 | Slimming composition and preparation method thereof |
| CN103735687A (en) * | 2013-12-30 | 2014-04-23 | 北京康比特体育科技股份有限公司 | Slimming composition and preparation method thereof |
| CN107156586A (en) * | 2017-06-02 | 2017-09-15 | 江苏朸健生命科技发展有限公司 | Advantageously reduce solid beverage of blood glucose and regulation blood fat and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 壹盛康品: ""控制血糖和肥胖的明星产品-α环状糊精"", pages 2, Retrieved from the Internet <URL:https://zhuanlan.zhihu.com/p/153287189> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645385B1 (en) | Composition for anti-obesity | |
| JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
| WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| EP2011500B1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
| KR20080105470A (en) | Food composition containing ginseng fruit extract for preventing and improving obesity | |
| US20030064937A1 (en) | Composition for reducing appetite in mammals | |
| WO2013078658A1 (en) | Morus berries and avoiding glucose peaks | |
| CN109745359A (en) | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof | |
| CN106136247A (en) | A kind of Semen Phaseoli Vulgaris many certain kind of berries compositions and preparation method thereof | |
| CN105935364B (en) | Composition comprising ginsenoside F2 for preventing or treating non-alcoholic liver disease | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| KR20150055876A (en) | Composition for reducing body-fat and weight | |
| KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
| KR20070113460A (en) | The health food composition for regulating weight | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| JP2008143811A (en) | Lipid metabolism promoting composition | |
| KR101045279B1 (en) | Composition of functional food with weight loss effect | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN110584120A (en) | Bone health composition | |
| CN115969045A (en) | Composition with weight health management function and preparation method and application thereof | |
| JP2007070263A (en) | Composition for preventing diabetes mellitus | |
| WO2014016265A1 (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| CN109364202B (en) | Composition and preparation method and application thereof | |
| US7416750B1 (en) | Composition to provide maintenance and nutritional support in glycemic control deficits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |